Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nephros (NEPH) Cost of Revenue (2016 - 2025)

Nephros (NEPH) has 16 years of Cost of Revenue data on record, last reported at $1.8 million in Q3 2025.

  • For Q3 2025, Cost of Revenue rose 35.06% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $6.6 million, up 24.9%, while the annual FY2024 figure was $5.4 million, 6.75% down from the prior year.
  • Cost of Revenue reached $1.8 million in Q3 2025 per NEPH's latest filing, up from $1.6 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.8 million in Q3 2025 and bottomed at $991000.0 in Q2 2021.
  • Average Cost of Revenue over 5 years is $1.4 million, with a median of $1.4 million recorded in 2024.
  • Peak YoY movement for Cost of Revenue: skyrocketed 46.82% in 2022, then fell 15.83% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $1.2 million in 2021, then fell by 15.54% to $1.0 million in 2022, then rose by 17.54% to $1.2 million in 2023, then grew by 13.14% to $1.4 million in 2024, then surged by 32.54% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $1.8 million in Q3 2025, $1.6 million in Q2 2025, and $1.7 million in Q1 2025.